GlassScriptPhysician profile
David H Jablonski
NPI 1134115819
$9,630.66
in general payments reported to CMS, 2019-2025
53 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $751 · 2021: $1,075 · 2022: $1,428 · 2023: $2,247 · 2024: $1,307 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,337.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $1,876.37 | 2020-2025 | Prolaris, Myrisk |
| Axonics, INC. | $1,236.46 | 2020-2024 | Axonics |
| Coloplast Corp | $948.84 | 2019-2025 | Speedicath |
| Astellas Pharma US INC | $559.85 | 2019-2023 | Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $489.96 | 2023-2025 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $431.85 | 2019-2023 | Xiaflex, Aveed |
| Ambu INC. | $343.40 | 2023-2025 | |
| Calyxo, INC. | $339.34 | 2024-2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $290.18 | 2021-2025 | Jelmyto |
| Pfizer INC. | $273.66 | 2019-2025 | |
| Boston Scientific Corporation | $256.73 | 2019-2025 | Axonics, Moses, Lithovue |
| Neotract INC. | $217.79 | 2019-2020 | |
| Allergan, INC. | $189.04 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $174.91 | 2024-2025 | Adstiladrin |
| Blue Earth Diagnostics | $164.89 | 2021-2025 | Posluma |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jablonski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.